TNF and rheumatoid arthritis: One of the most successful bDMARD for the treatment of active RA is original adalimumab, a fully human recombinant monoclonal antibody (immunoglobulin G1), derived by phage display, which targets with high affinity and specificity tumor necrosis factor α (TNFα) [5], a key cytokine in the pathogenic process of RA [6].